Ten‐year survivors in AL amyloidosis: characteristics and treatment pattern
Open Access
- 12 July 2019
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 187 (5) , 588-594
Abstract
Summary: Improvement in survival in Light chain (AL) amyloidosis has been seen over recent decades, enabling more patients to achieve long‐term survival. Patients with AL amyloidosis who survived ≥10 years from time of diagnosis (n = 186) were the subject of this study. Ten‐year survivors represented 22% of the total population. These patients were characterized by favourable patient, organ and plasma cell features. Of note, trisomies were less common among 10‐year survivors compared to those who did not survive to 10 years. All‐time best haematological response was complete response in 67%, very good partial response in 30%, partial response in 2% and no response in 1%, with 11% having received a consolidative strategy for inadequate response to first line therapy. The overall organ response rate to first‐line therapy was 76%, which increased to 86% when considering subsequent line(s) of therapy. Forty‐seven percent of the 10‐year survivors did not require a second‐line therapy. The median treatment‐free survival (TFS) among the 10‐year survivors was 10·5 years (interquartile range 7·4‐12·2). On multivariate analysis independent predictors for TFS were the achievement of complete haematological response and lack of cardiac involvement. Long‐term survivors are increasingly seen in AL amyloidosis and present distinct patient, organ and clonal disease features.Keywords
Funding Information
- National Cancer Institute (P50 CA186781)
This publication has 21 references indexed in Scilit:
- Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survivalLeukemia, 2016
- Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and TherapyActa Haematologica, 2016
- Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosisLeukemia Research, 2015
- Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for deathBlood Cancer Journal, 2015
- Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based RegimensJournal of Clinical Oncology, 2015
- A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosisBlood, 2014
- Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor LoadJournal of Clinical Oncology, 2013
- Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaLeukemia, 2013
- New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival OutcomesJournal of Clinical Oncology, 2012
- Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and AmyloidosisAmerican Journal of Hematology, 2005